These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 21191361)

  • 1. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
    Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
    Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we eliminate both calcineurin inhibitors and steroids?
    Lebranchu Y
    Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
    Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
    Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
    Guba M; Pratschke J; Hugo C; Krämer BK; Pascher A; Pressmar K; Hakenberg O; Fischereder M; Brockmann J; Andrassy J; Banas B; Jauch KW;
    Transpl Int; 2012 Apr; 25(4):416-23. PubMed ID: 22320241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
    Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
    Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.